Detailed Information on Publication Record
2021
MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy
BOHOŠOVÁ, Júlia, Jiří VAJČNER, Petr JABANDŽIEV, Hana OŠLEJŠKOVÁ, Ondřej SLABÝ et. al.Basic information
Original name
MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy
Authors
BOHOŠOVÁ, Júlia (703 Slovakia, belonging to the institution), Jiří VAJČNER (203 Czech Republic, belonging to the institution), Petr JABANDŽIEV (203 Czech Republic, belonging to the institution), Hana OŠLEJŠKOVÁ (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Štefánia AULICKÁ (703 Slovakia, guarantor, belonging to the institution)
Edition
Epilepsia, Hoboken, Wiley-Blackwell, 2021, 0013-9580
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30210 Clinical neurology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 6.740
RIV identification code
RIV/00216224:14110/21:00120160
Organization unit
Faculty of Medicine
UT WoS
000692515800001
Keywords in English
biomarkers; drug-resistant epilepsy; intractable epilepsy; noncoding RNA; refractory epilepsy
Tags
International impact, Reviewed
Změněno: 28/2/2022 07:22, Mgr. Tereza Miškechová
Abstract
V originále
Although many new antiseizure drugs have been developed in the past decade, approximately 30%-40% of patients remain pharmacoresistant. There are no clinical tools or guidelines for predicting therapeutic response in individual patients, leaving them no choice other than to try all antiseizure drugs available as they suffer debilitating seizures with no relief. The discovery of predictive biomarkers and early identification of pharmacoresistant patients is of the highest priority in this group. MicroRNAs (miRNAs), a class of short noncoding RNAs negatively regulating gene expression, have emerged in recent years in epilepsy, following a broader trend of their exploitation as biomarkers of various complex human diseases. We performed a systematic search of the PubMed database for original research articles focused on miRNA expression level profiling in patients with drug-resistant epilepsy or drug-resistant precilinical models and cell cultures. In this review, we summarize 17 publications concerning miRNAs as potential new biomarkers of resistance to antiseizure drugs and their potential role in the development of drug resistance or epilepsy. Although numerous knowledge gaps need to be filled and reviewed, and articles share some study design pitfalls, several miRNAs dysregulated in brain tissue and blood serum were identified independently by more than one paper. These results suggest a unique opportunity for disease monitoring and personalized therapeutic management in the future.
Links
| NU21-04-00305, research and development project |
|